FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 Daily News for Neuros, Nurses & Savvy MSers: 208,152 Viewers, 8,368 Stories & Studies
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Wednesday

 

New Compound Tested in Lab Shows Promise for Progressive Multiple Sclerosis

























Exploratory research conducted at Virginia Commonwealth University and the University of Illinois at Chicago may translate into a new therapeutic agent to treat progressive multiple sclerosis. Researchers in the laboratories of Dr. Jefferey L. Dupree and Dr. Douglas L. Feinstein tested a new compound in mice with induced multiple sclerosis and found that the compound reduced neurodegeneration and helped improve symptoms.

The compound, lanthionine ketimine, is a naturally occurring molecule that binds to collapsin response mediator protein-2 (CRMP2), which is a protein found in the brain that helps regulate vital neuronal activities. In order to use this compound to treat mice with induced multiple sclerosis, the researchers needed to chemically modify it into a cell-permeable state. The resulting molecule was lanthionine ketimine ethyl-ester (LKE), which was shown to promote neurogenesis and healthy nervous system function.

As explained in the journal article, “Lanthionine Ketimine Ester Provides Benefit in a Mouse Model of Multiple Sclerosis,” which was published in Journal of Neurochemistry, the authors induced multiple sclerosis in mice using the well-accepted model of experimental autoimmune encephalomyelitis (EAE). After mice began to show moderate clinical symptoms of multiple sclerosis, the researchers mixed LKE into the animals’ food so that mice were treated whenever they decided to eat.

After four weeks of ingesting LKE, mice had lower levels of inflammation than those that did not receive LKE but were induced with EAE. LKE-treated mice also showed lower degeneration of the optic nerve and spinal cord, showing only minimal damage to the myelin sheath around the axons. The protective effect was more pronounced in the optic nerve, but the spinal cord also showed great benefit from LKE treatment.

If the researchers continue to pursue LKE and design a well-controlled dosing study in other animal models of multiple sclerosis, the compound may be a potential candidate for clinical trials in patients with progressive multiple sclerosis. “Only few drugs have been shown to reduce neurodegeneration in multiple sclerosis,” stated the authors. By identifying neuronal protection in the spinal cord and optic nerve, the researchers showed that LKE is a novel and strong candidate for testing in progressive multiple sclerosis.

Story Source: The above story is based on materials provided by MULTIPLESCLEROSISNEWSTODAY
Note: Materials may be edited for content and length

Labels:



Go to Newer News Go to Older News